Table 2.
Multivariable logistic model of the risk of low (<1 month) and high adherence (≥6 months); DDD analysis.
| Low Adherence (< 1 Month) | High Adherence (≥ 6 Months) | |||
|---|---|---|---|---|
| Parameter | OR (95% CI) | p-valuea | OR (95% CI) | p-valuea |
| Antidepressant | - | - | - | - |
| Vortioxetine (REF) | - | - | - | - |
| Citalopram | 0.549 (0.396-0.760) | 0.0003 | 1.01 (0.794-1.285) | 0.9347 |
| Duloxetine | 2.099 (1.535-2.871) | <.0001 | 1.119 (0.856-1.462) | 0.4127 |
| Escitalopram | 0.734 (0.551-0.977) | 0.0344 | 1.126 (0.900-1.408) | 0.2994 |
| Paroxetine | 1.341 (1.016-1.769) | 0.0384 | 0.886 (0.706-1.11) | 0.2927 |
| Sertraline | 0.109 (0.072-0.166) | <0.0001 | 1.564 (1.250-1.957) | <0.0001 |
| Venlafaxine | 3.248 (2.401-4.393) | <0.0001 | 0.599 (0.452-0.794) | 0.0004 |
| Sex | - | - | - | - |
| Male (REF) | - | - | - | - |
| Female | 1.01 (0.881-1.159) | 0.8850 | 1.079 (0.975-1.194) | 0.1424 |
| Age group category, years | - | - | - | - |
| 18-40 (REF) | - | - | - | - |
| 41-64 | 0.896 (0.730-1.101) | 0.2972 | 1.159 (0.986-1.361) | 0.0735 |
| ≥65 | 0.797 (0.636-0.999) | 0.0485 | 1.191 (1.002-1.415) | 0.0478 |
| Previous AD treatment 10 years before index date | - | - | - | - |
| No (REF) | - | - | - | - |
| Unknown | 0.817 (0.672-0.993) | 0.0423 | 1.326 (1.151-1.527) | <0.0001 |
| Yes | 0.787 (0.686-0.903) | 0.0006 | 0.991 (0.894-1.097) | 0.8573 |
| Comorbidity | - | - | - | - |
| Hypertension | 1.006 (0.870-1.163) | 0.9359 | 1.053 (0.947-1.171) | 0.3407 |
| Diabetes (type 1 or 2) | 0.925 (0.758-1.128) | 0.4422 | 0.968 (0.841-1.116) | 0.6577 |
| Coronary Artery Disease | 1.389 (1.096-1.761) | 0.0065 | 0.796 (0.664-0.954) | 0.0134 |
| Cerebrovascular Disease | 0.862 (0.692-1.073) | 0.1826 | 1.196 (1.031-1.387) | 0.0182 |
| Anxiety | 1.068 (0.872-1.307) | 0.5253 | 1.201 (1.035-1.393) | 0.0155 |
a Values in bold indicate parameters with significantly increased risk of low adherence/likelihood of high adherence.
CI, confidence interval; OR, odds ratio; REF, reference.